Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain in mice
Autor: | Agustín Hidalgo, Eva García, Lucía Juárez, Ana Baamonde, Luis Menéndez, Olivia García-Suárez |
---|---|
Rok vydání: | 2006 |
Předmět: |
musculoskeletal diseases
Agonist medicine.medical_specialty Time Factors medicine.drug_class Freund's Adjuvant Analgesic Resiniferatoxin TRPV1 Pain Bone Neoplasms Functional Laterality Cell Line Mice chemistry.chemical_compound Internal medicine Reaction Time medicine Animals Pain Measurement Inflammation Analgesics Analysis of Variance Mice Inbred C3H Osteosarcoma Dose-Response Relationship Drug business.industry General Neuroscience Antagonist nervous system diseases Disease Models Animal Endocrinology chemistry Freund's adjuvant Hyperalgesia Capsaicin Diterpenes medicine.symptom Capsazepine business |
Zdroj: | Neuroscience Letters. 393:70-73 |
ISSN: | 0304-3940 |
DOI: | 10.1016/j.neulet.2005.09.046 |
Popis: | In the present paper, we describe the analgesic effects induced by the transient receptor potential vanilloid type 1 (TRPV1) antagonist, capsazepine, and the TRPV1 agonist, resiniferatoxin, on the thermal hyperalgesia induced by the presence of a tibial osteosarcoma or an inflammatory process in mice. The administration of capsazepine abolished the osteosarcoma-induced hyperalgesia at a dose range (3-10 mg/kg; s.c.) ineffective to inhibit the hyperalgesia elicited by the intraplantar administration of complete Freund's adjuvant (CFA). In contrast, the administration of resiniferatoxin (0.01-0.1 mg/kg; s.c.) inhibited both the osteosarcoma- and the CFA-induced hyperalgesia. Remarkably, a single dose of resiniferatoxin abolished the osteosarcoma-induced hyperalgesia for several days and completely prevented the instauration of thermal hyperalgesia when administered at the initial stages of osteosarcoma development. The potential of drugs acting through TRPV1 for the management of some types of bone cancer pain is proposed. |
Databáze: | OpenAIRE |
Externí odkaz: |